Tag: Multiple

Latest News

Takeda présente des données positives dans le cadre de l’essai clinique évaluant la prise orale de NINLARO™ (ixazomib) comme traitement d’entretien de première intention contre le myélome multiple

Newsemia
CAMBRIDGE, Massachusetts, & OSAKA, Japon–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE : 4502/NYSE : TAK) (« Takeda ») a annoncé aujourd’hui qu’elle présenterait oralement les résultats...
Latest News

Takeda presenta datos positivos del estudio clínico para la evaluación de NINLARO™ (ixazomib) como terapia de mantenimiento para el mieloma múltiple

Newsemia
CAMBRIDGE, Massachusetts y OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) anunció el día de la fecha que presentará oralmente los resultados de dos estudios...
Pharma / Biotech

First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased Sphingosine-1 phosphate receptor-1 agonist for endothelial protection.

Newsemia
Related Articles First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased Sphingosine-1 phosphate receptor-1...
Latest News

Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models

Newsemia
Schuh, C; Wimmer, I; Hametner, S; Haider, L; Van Dam, A-M; Liblau, RS; Smith, KJ; … Lassmann, H; + view all Schuh, C; Wimmer, I;...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World